The role of vitamin D in cancer prevention and treatment

Endocrinology and Metabolism Clinics of North America

Volumn 39, Issue 2, 2010, Pages 401-418

  Krishnan, Aruna V ^a   Trump, Donald L ^b   Johnson, Candace S ^b   Feldman, David ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Antiinflammation; Antiproliferation; Cancer; Gene regulation; Prevention; Treatment; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ANTINEOPLASTIC ANTIMETABOLITE; CALCITRIOL; CARBOPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLOOXYGENASE 2; CYTOCHROME P450; CYTOCHROME P450 24; DEXAMETHASONE; DOCETAXEL; GEFITINIB; HYPOXIA INDUCIBLE FACTOR 1; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 5; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; PLACEBO; PREDNISONE; PROSTAGLANDIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN P73; SOMATOMEDIN BINDING PROTEIN 3; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VITAMIN D RECEPTOR;

ABSENCE OF SIDE EFFECTS; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CALCIUM BLOOD LEVEL; CANCER CELL DESTRUCTION; CANCER INCIDENCE; CANCER INVASION; CANCER PREVENTION; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CLINICAL TRIAL; COLORECTAL CANCER; DEPHOSPHORYLATION; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; GENE EXPRESSION; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; KIDNEY DYSFUNCTION; MAXIMUM TOLERATED DOSE; METASTASIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROSTATE CANCER; PROSTATE TUMOR; PROSTATIC INTRAEPITHELIAL NEOPLASIA; REVIEW; RISK REDUCTION; SIDE EFFECT; SIGNAL TRANSDUCTION; SUN EXPOSURE; TRANSCRIPTION INITIATION; VITAMIN BLOOD LEVEL;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; CALCITRIOL; CLINICAL TRIALS AS TOPIC; DUAL-SPECIFICITY PHOSPHATASES; HUMANS; MALE; MICE; MITOGEN-ACTIVATED PROTEIN KINASE PHOSPHATASES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; PROSTAGLANDINS; VITAMIN D;

ANIMALIA;

EID: 77953928495     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2010.02.011     Document Type: Review

References (148)

1. Feldman D., Malloy P.J., Krishnan A.V., et al. Vitamin D: biology, action and clinical implications. Osteoporosis 2007, vol. 1:317-382. Academic Press, San Diego (CA). 3rd edition. R. Marcus, D. Feldman, D.A. Nelson (Eds.).
2. Deeb K.K., Trump D.L., Johnson C.S. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 2007, 7(9):684-700.
3. Garland C.F., Garland F.C. Do sunlight and vitamin D reduce the likelihood of colon cancer?. Int J Epidemiol 1980, 9(3):227-231.
4. Hanchette C.L., Schwartz G.G. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer 1992, 70(12):2861-2869.
5. Schwartz G.G., Hulka B.S. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 1990, 10(5A):1307-1311.
6. Garland C.F., Garland F.C., Gorham E.D., et al. The role of vitamin D in cancer prevention. Am J Public Health 2006, 96(2):252-261.
7. Giovannucci E. Vitamin D status and cancer incidence and mortality. Adv Exp Med Biol 2008, 624:31-42.
8. Garland C.F., Gorham E.D., Mohr S.B., et al. Vitamin D and prevention of breast cancer: pooled analysis. J Steroid Biochem Mol Biol 2007, 103(3-5):708-711.
9. Wei M.Y., Garland C.F., Gorham E.D., et al. Vitamin D and prevention of colorectal adenoma: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2008, 17(11):2958-2969.
10. Yin L., Grandi N., Raum E., et al. Meta-analysis: longitudinal studies of serum vitamin D and colorectal cancer risk. Aliment Pharmacol Ther 2009, 30(2):113-125.
11. Ng K., Meyerhardt J.A., Wu K., et al. Circulating 25-hydroxyvitamin D levels and survival in patients with colorectal cancer. J Clin Oncol 2008, 26(18):2984-2991.
12. Ding E.L., Mehta S., Fawzi W.W., et al. Interaction of estrogen therapy with calcium and vitamin D supplementation on colorectal cancer risk: reanalysis of Women's Health Initiative randomized trial. Int J Cancer 2008, 122(8):1690-1694.
13. Corder E.H., Friedman G.D., Vogelman J.H., et al. Seasonal variation in vitamin D, vitamin D-binding protein, and dehydroepiandrosterone: risk of prostate cancer in black and white men. Cancer Epidemiol Biomarkers Prev 1995, 4(6):655-659.
14. Corder E.H., Guess H.A., Hulka B.S., et al. Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 1993, 2(5):467-472.
15. Ahn J., Peters U., Albanes D., et al. Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst 2008, 100(11):796-804.
16. Platz E.A., Leitzmann M.F., Hollis B.W., et al. Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control 2004, 15(3):255-265.
17. Ahonen M.H., Tenkanen L., Teppo L., et al. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 2000, 11(9):847-852.
18. Garland C.F., Comstock G.W., Garland F.C., et al. Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study. Lancet 1989, 2(8673):1176-1178.
19. Skinner H.G., Michaud D.S., Giovannucci E., et al. Vitamin D intake and the risk for pancreatic cancer in two cohort studies. Cancer Epidemiol Biomarkers Prev 2006, 15(9):1688-1695.
20. Chiang K.C., Chen T.C. Vitamin D for the prevention and treatment of pancreatic cancer. World J Gastroenterol 2009, 15(27):3349-3354.
21. Colston K.W., Welsh J. Vitamin D and breast cancer. Vitamin D 2005, vol. 2:1663-1677. Elsevier Academic Press, San Diego (CA). D. Feldman, J.W. Pike, F.H. Glorieux (Eds.).
22. Cross H.S. Vitamin D and colon cancer. Vitamin D 2005, vol. 2:1709-1725. Elsevier Academic Press, San Diego (CA). D. Feldman, J.W. Pike, F.H. Glorieux (Eds.).
23. Gombart A.F., Luong Q.T., Koeffler H.P. Vitamin D compounds: activity against microbes and cancer. Anticancer Res 2006, 26(4A):2531-2542.
24. Gonzalez-Sancho J.M., Larriba M.J., Ordonez-Moran P., et al. Effects of 1alpha, 25-dihydroxyvitamin D3 in human colon cancer cells. Anticancer Res 2006, 26(4A):2669-2681.
25. Gross M.D. Vitamin D and calcium in the prevention of prostate and colon cancer: new approaches for the identification of needs. J Nutr 2005, 135(2):326-331.
26. Krishnan A.V., Peehl D.M., Feldman D. Inhibition of prostate cancer growth by vitamin D: regulation of target gene expression. J Cell Biochem 2003, 88(2):363-371.
27. Krishnan A.V., Peehl D.M., Feldman D. Vitamin D and prostate cancer. Vitamin D 2005, vol. 2:1679-1707. Elsevier Academic Press, San Diego (CA). 2nd edition. D. Feldman, J.W. Pike, F.H. Glorieux (Eds.).
28. Luong Q.T., Koeffler H.P. Vitamin D compounds in leukemia. J Steroid Biochem Mol Biol 2005, 97(1-2):195-202.
29. Schwartz G.G., Skinner H.G. Vitamin D status and cancer: new insights. Curr Opin Clin Nutr Metab Care 2007, 10(1):6-11.
30. Stewart L.V., Weigel N.L. Vitamin D and prostate cancer. Exp Biol Med (Maywood) 2004, 229(4):277-284.
31. Welsh J. Targets of vitamin D receptor signaling in the mammary gland. J Bone Miner Res 2007, 22(Suppl 2):V86-V90.
32. Campbell M.J., Elstner E., Holden S., et al. Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin. J Mol Endocrinol 1997, 19(1):15-27.
33. Yang E.S., Burnstein K.L. Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm. J Biol Chem 2003, 278(47):46862-46868.
34. Blutt S.E., Allegretto E.A., Pike J.W., et al. 1,25-Dihydroxyvitamin D3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. Endocrinology 1997, 138(4):1491-1497.
35. Jensen S.S., Madsen M.W., Lukas J., et al. Inhibitory effects of 1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. Mol Endocrinol 2001, 15(8):1370-1380.
36. Ma Y., Yu W.D., Hershberger P.A., et al. 1alpha,25-Dihydroxyvitamin D3 potentiates cisplatin antitumor activity by p73 induction in a squamous cell carcinoma model. Mol Cancer Ther 2008, 7(9):3047-3055.
37. Boyle B.J., Zhao X.Y., Cohen P., et al. Insulin-like growth factor binding protein-3 mediates 1 alpha,25-dihydroxyvitamin d(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. J Urol 2001, 165(4):1319-1324.
38. Peng L., Malloy P.J., Feldman D. Identification of a functional vitamin D response element in the human insulin-like growth factor binding protein-3 promoter. Mol Endocrinol 2004, 18:1109-1119.
39. Gocek E., Studzinski G.P. Vitamin D and differentiation in cancer. Crit Rev Clin Lab Sci 2009, 46(4):190-209.
40. Blutt S.E., McDonnell T.J., Polek T.C., et al. Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology 2000, 141(1):10-17.
41. Narvaez C.J., Welsh J. Role of mitochondria and caspases in vitamin D-mediated apoptosis of MCF-7 breast cancer cells. J Biol Chem 2001, 276(12):9101-9107.
42. Ylikomi T., Laaksi I., Lou Y.R., et al. Antiproliferative action of vitamin D. Vitam Horm 2002, 64:357-406.
43. Park W.H., Seol J.G., Kim E.S., et al. Induction of apoptosis by vitamin D3 analogue EB1089 in NCI-H929 myeloma cells via activation of caspase 3 and p38 MAP kinase. Br J Haematol 2000, 109(3):576-583.
44. Posner G.H., Crawford K.R., Peleg S., et al. A non-calcemic sulfone version of the vitamin D(3) analogue seocalcitol (EB 1089): chemical synthesis, biological evaluation and potency enhancement of the anticancer drug adriamycin. Bioorg Med Chem 2001, 9(9):2365-2371.
45. Sundaram S., Sea A., Feldman S., et al. The combination of a potent vitamin D3 analog, EB 1089, with ionizing radiation reduces tumor growth and induces apoptosis of MCF-7 breast tumor xenografts in nude mice. Clin Cancer Res 2003, 9(6):2350-2356.
46. Getzenberg R.H., Light B.W., Lapco P.E., et al. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology 1997, 50(6):999-1006.
47. Nakagawa K., Kawaura A., Kato S., et al. 1 alpha,25-Dihydroxyvitamin D(3) is a preventive factor in the metastasis of lung cancer. Carcinogenesis 2005, 26(2):429-440.
48. Koli K., Keski-Oja J. 1alpha,25-dihydroxyvitamin D3 and its analogues down-regulate cell invasion-associated proteases in cultured malignant cells. Cell Growth Differ 2000, 11(4):221-229.
49. Gonzalez-Sancho J.M., Alvarez-Dolado M., Munoz A. 1,25-Dihydroxyvitamin D3 inhibits tenascin-C expression in mammary epithelial cells. FEBS Lett 1998, 426(2):225-228.
50. Sung V., Feldman D. 1,25-Dihydroxyvitamin D3 decreases human prostate cancer cell adhesion and migration. Mol Cell Endocrinol 2000, 164(1-2):133-143.
51. Bao B.Y., Yeh S.D., Lee Y.F. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell invasion via modulation of selective proteases. Carcinogenesis 2006, 27(1):32-42.
52. Allavena P., Garlanda C., Borrello M.G., et al. Pathways connecting inflammation and cancer. Curr Opin Genet Dev 2008, 18(1):3-10.
53. De Marzo A.M., Platz E.A., Sutcliffe S., et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007, 7(4):256-269.
54. Mantovani A., Allavena P., Sica A., et al. Cancer-related inflammation. Nature 2008, 454(7203):436-444.
55. Lucia M.S., Torkko K.C. Inflammation as a target for prostate cancer chemoprevention: pathological and laboratory rationale. J Urol 2004, 171(2 Pt 2):S30-S34. [discussion: S35].
56. Mantovani A., Pierotti M.A. Cancer and inflammation: a complex relationship. Cancer Lett 2008, 267(2):180-181.
57. Angelo L.S., Kurzrock R. Vascular endothelial growth factor and its relationship to inflammatory mediators. Clin Cancer Res 2007, 13(10):2825-2830.
58. Kundu J.K., Surh Y.J. Inflammation: gearing the journey to cancer. Mutat Res 2008, 659(1-2):15-30.
59. Moran E.M. Epidemiological and clinical aspects of nonsteroidal anti-inflammatory drugs and cancer risks. J Environ Pathol Toxicol Oncol 2002, 21(2):193-201.
60. Thun M.J., Henley S.J., Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002, 94(4):252-266.
61. Krishnan A.V., Shinghal R., Raghavachari N., et al. Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays. Prostate 2004, 59(3):243-251.
62. Peehl D.M., Shinghal R., Nonn L., et al. Molecular activity of 1,25-dihydroxyvitamin D3 in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis. J Steroid Biochem Mol Biol 2004, 92(3):131-141.
63. McCarty M.F. Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy. Integr Cancer Ther 2004, 3(4):349-380.
64. Maeda S., Omata M. Inflammation and cancer: role of nuclear factor-kappaB activation. Cancer Sci 2008, 99(5):836-842.
65. Moreno J., Krishnan A.V., Swami S., et al. Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res 2005, 65(17):7917-7925.
66. Srinivas S., Feldman D. A phase II trial of calcitriol and naproxen in recurrent prostate cancer. Anticancer Res 2009, 29(9):3605-3610.
67. Nonn L., Peng L., Feldman D., et al. Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via mitogen-activated protein kinase phosphatase 5: implications for prostate cancer prevention by vitamin D. Cancer Res 2006, 66(8):4516-4524.
68. Culig Z., Steiner H., Bartsch G., et al. Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem 2005, 95(3):497-505.
69. Finley D.S., Calvert V.S., Inokuchi J., et al. Periprostatic adipose tissue as a modulator of prostate cancer aggressiveness. J Urol 2009, 182(4):1621-1627.
70. Karin M., Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 2002, 3(3):221-227.
71. Ghosh S., Karin M. Missing pieces in the NF-kappaB puzzle. Cell 2002, 109(Suppl):S81-S96.
72. Palayoor S.T., Youmell M.Y., Calderwood S.K., et al. Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. Oncogene 1999, 18(51):7389-7394.
73. Sovak M.A., Bellas R.E., Kim D.W., et al. Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 1997, 100(12):2952-2960.
74. Yu X.P., Bellido T., Manolagas S.C. Down-regulation of NF-kappa B protein levels in activated human lymphocytes by 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci U S A 1995, 92(24):10990-10994.
75. Harant H., Wolff B., Lindley I.J. 1Alpha,25-dihydroxyvitamin D3 decreases DNA binding of nuclear factor-kappaB in human fibroblasts. FEBS Lett 1998, 436(3):329-334.
76. Stio M., Martinesi M., Bruni S., et al. The vitamin D analogue TX 527 blocks NF-kappaB activation in peripheral blood mononuclear cells of patients with Crohn's disease. J Steroid Biochem Mol Biol 2007, 103(1):51-60.
77. Sun J., Kong J., Duan Y., et al. Increased NF-kappaB activity in fibroblasts lacking the vitamin D receptor. Am J Physiol Endocrinol Metab 2006, 291(2):E315-E322.
78. Schwab M., Reynders V., Loitsch S., et al. Involvement of different nuclear hormone receptors in butyrate-mediated inhibition of inducible NF kappa B signalling. Mol Immunol 2007, 44(15):3625-3632.
79. Bao B.Y., Yao J., Lee Y.F. 1alpha, 25-Dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis 2006, 27(9):1883-1893.
80. Jogie-Brahim S., Feldman D., Oh Y. Unraveling IGFBP-3 actions in human disease. Endocr Rev 2009, 30(5):417-437.
81. Criswell T., Leskov K., Miyamoto S., et al. Transcription factors activated in mammalian cells after clinically relevant doses of ionizing radiation. Oncogene 2003, 22(37):5813-5827.
82. Kimura K., Bowen C., Spiegel S., et al. Tumor necrosis factor-alpha sensitizes prostate cancer cells to gamma-irradiation-induced apoptosis. Cancer Res 1999, 59(7):1606-1614.
83. Xu Y., Fang F., St Clair D.K., et al. Suppression of RelB-mediated manganese superoxide dismutase expression reveals a primary mechanism for radiosensitization effect of 1alpha,25-dihydroxyvitamin D(3) in prostate cancer cells. Mol Cancer Ther 2007, 6(7):2048-2056.
84. De Marzo A.M., DeWeese T.L., Platz E.A., et al. Pathological and molecular mechanisms of prostate carcinogenesis: implications for diagnosis, detection, prevention, and treatment. J Cell Biochem 2004, 91(3):459-477.
85. De Marzo A.M., Marchi V.L., Epstein J.I., et al. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 1999, 155(6):1985-1992.
86. Zha S., Gage W.R., Sauvageot J., et al. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res 2001, 61(24):8617-8623.
87. Herszenyi L., Miheller P., Tulassay Z. Carcinogenesis in inflammatory bowel disease. Dig Dis 2007, 25(3):267-269.
88. Itzkowitz S.H., Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 2004, 287(1):G7-17.
89. Seril D.N., Liao J., Yang G.Y., et al. Oxidative stress and ulcerative colitis-associated carcinogenesis: studies in humans and animal models. Carcinogenesis 2003, 24(3):353-362.
90. Whittemore A.S., Cirillo P.M., Feldman D., et al. Prostate specific antigen levels in young adulthood predict prostate cancer risk: results from a cohort of black and white Americans. J Urol 2005, 174(3):872-876. [discussion: 876].
91. Gupta S., Adhami V.M., Subbarayan M., et al. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2004, 64(9):3334-3343.
92. Alagbala A, Moser MT, Johnson CS, et al. Prevention of prostate cancer progression with vitamin D compounds in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Presented at the 4th Annual AACR International Conference on Frontiers in Cancer Prevention Research. Baltimore (MD), October 30 to November 2, 2005.
93. Alagbala AA, Moser MT, Johnson CS, et al. 1a,25-Dihydroxyvitamin D3 and its analog (QW-1624F2-2) prevent prostate cancer progression. Presented at 13th Workshop on Vitamin D. Victoria, BC (Canada), April 8-12, 2006.
94. Banach-Petrosky W., Ouyang X., Gao H., et al. Vitamin D inhibits the formation of prostatic intraepithelial neoplasia in Nkx3.1;Pten mutant mice. Clin Cancer Res 2006, 12(19):5895-5901.
95. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1(1):27-31.
96. Sakamoto S., Ryan A.J., Kyprianou N. Targeting vasculature in urologic tumors: mechanistic and therapeutic significance. J Cell Biochem 2008, 103(3):691-708.
97. Giaccia A., Siim B.G., Johnson R.S. HIF-1 as a target for drug development. Nat Rev Drug Discov 2003, 2(10):803-811.
98. Rankin E.B., Giaccia A.J. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 2008, 15(4):678-685.
99. Majewski S., Skopinska M., Marczak M., et al. Vitamin D3 is a potent inhibitor of tumor cell-induced angiogenesis. J Investig Dermatol Symp Proc 1996, 1(1):97-101.
100. Mantell D.J., Owens P.E., Bundred N.J., et al. 1 alpha,25-Dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res 2000, 87(3):214-220.
101. Ben-Shoshan M., Amir S., Dang D.T., et al. 1alpha,25-Dihydroxyvitamin D3 (calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells. Mol Cancer Ther 2007, 6(4):1433-1439.
102. Bernardi R.J., Johnson C.S., Modzelewski R.A., et al. Antiproliferative effects of 1alpha,25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial cells. Endocrinology 2002, 143(7):2508-2514.
103. Chung I., Han G., Seshadri M., et al. Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo. Cancer Res 2009, 69(3):967-975.
104. Fukuda R., Kelly B., Semenza G.L. Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. Cancer Res 2003, 63(9):2330-2334.
105. McElwain M.C., Dettelbach M.A., Modzelewski R.A., et al. Antiproliferative effects in vitro and in vivo of 1,25-dihydroxyvitamin D3 and a vitamin D3 analog in a squamous cell carcinoma model system. Mol Cell Differ 1995, 3(1):31-50.
106. Zhang X., Jiang F., Li P., et al. Growth suppression of ovarian cancer xenografts in nude mice by vitamin D analogue EB1089. Clin Cancer Res 2005, 11(1):323-328.
107. Colston K.W., Chander S.K., Mackay A.G., et al. Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem Pharmacol 1992, 44(4):693-702.
108. Welsh J., Wietzke J.A., Zinser G.M., et al. Vitamin D-3 receptor as a target for breast cancer prevention. J Nutr 2003, 133(Suppl 7):2425S-2433S.
109. Ma Y, Yu WD, Trump DL, et al. 1,25D3 enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models. Cancer 2010, in press.
110. Colston K.W., James S.Y., Ofori-Kuragu E.A., et al. Vitamin D receptors and anti-proliferative effects of vitamin D derivatives in human pancreatic carcinoma cells in vivo and in vitro. Br J Cancer 1997, 76(8):1017-1020.
111. Moore T.B., Koeffler H.P., Yamashiro J.M., et al. Vitamin D3 analogs inhibit growth and induce differentiation in LA-N-5 human neuroblastoma cells. Clin Exp Metastasis 1996, 14(3):239-245.
112. Chung I., Wong M.K., Flynn G., et al. Differential antiproliferative effects of calcitriol on tumor-derived and Matrigel-derived endothelial cells. Cancer Res 2006, 66(17):8565-8573.
113. Chung I., Karpf A.R., Muindi J.R., et al. Epigenetic silencing of CYP24 in tumor-derived endothelial cells contributes to selective growth inhibition by calcitriol. J Biol Chem 2007, 282(12):8704-8714.
114. Ly L.H., Zhao X.Y., Holloway L., et al. Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Endocrinology 1999, 140(5):2071-2076.
115. Miller G.J., Stapleton G.E., Hedlund T.E., et al. Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1alpha,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines. Clin Cancer Res 1995, 1(9):997-1003.
116. Peehl D.M., Seto E., Hsu J.Y., et al. Preclinical activity of ketoconazole in combination with calcitriol or the vitamin D analogue EB 1089 in prostate cancer cells. J Urol 2002, 168(4 Pt 1):1583-1588.
117. Hershberger P.A., McGuire T.F., Yu W.D., et al. Cisplatin potentiates 1,25-dihydroxyvitamin D3-induced apoptosis in association with increased mitogen-activated protein kinase kinase kinase 1 (MEKK-1) expression. Mol Cancer Ther 2002, 1(10):821-829.
118. Moffatt K.A., Johannes W.U., Miller G.J. 1alpha,25-Dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines. Clin Cancer Res 1999, 5(3):695-703.
119. Hershberger P.A., Yu W.D., Modzelewski R.A., et al. Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res 2001, 7(4):1043-1051.
120. Trump D.L., Hershberger P.A., Bernardi R.J., et al. Anti-tumor activity of calcitriol: pre-clinical and clinical studies. J Steroid Biochem Mol Biol 2004, 89-90(1-5):519-526.
121. Muindi JR, Yu WD, Ma Y, et al. CYP24A1 inhibition enhances the antitumor activity of calcitriol. Submitted for publication, 2010.
122. Rochlitz C.F., Damon L.E., Russi M.B., et al. Cytotoxicity of ketoconazole in malignant cell lines. Cancer Chemother Pharmacol 1988, 21(4):319-322.
123. Kahraman M., Sinishtaj S., Dolan P.M., et al. Potent, selective and low-calcemic inhibitors of CYP24 hydroxylase: 24-sulfoximine analogues of the hormone 1alpha,25-dihydroxyvitamin D(3). J Med Chem 2004, 47(27):6854-6863.
124. Lechner D., Manhardt T., Bajna E., et al. A 24-phenylsulfone analog of vitamin D inhibits 1alpha,25-dihydroxyvitamin D(3) degradation in vitamin D metabolism-competent cells. J Pharmacol Exp Ther 2007, 320(3):1119-1126.
125. Gallagher J.C. Metabolic effects of synthetic calcitriol (Rocaltrol) in the treatment of postmenopausal osteoporosis. Metabolism 1990, 39(4 Suppl 1):27-29.
126. Gallagher J.C., Goldgar D. Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study. Ann Intern Med 1990, 113(9):649-655.
127. Gross C., Stamey T., Hancock S., et al. Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J Urol 1998, 159(6):2035-2039. [discussion: 2039-40].
128. Osborn J.L., Schwartz G.G., Smith D.C., et al. 1,25-Dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. Urol Oncol 1995, 1(5):195-198.
129. Muindi J.R., Peng Y., Potter D.M., et al. Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel. Clin Pharmacol Ther 2002, 72(6):648-659.
130. Muindi J.R., Potter D.M., Peng Y., et al. Pharmacokinetics of liquid calcitriol formulation in advanced solid tumor patients: comparison with caplet formulation. Cancer Chemother Pharmacol 2005, 56(5):492-496.
131. Beer T.M., Munar M., Henner W.D. A phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation. Cancer 2001, 91(12):2431-2439.
132. Beer T.M., Javle M., Lam G.N., et al. Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer. Clin Cancer Res 2005, 11(21):7794-7799.
133. Beer T.M., Javle M.M., Ryan C.W., et al. Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer. Cancer Chemother Pharmacol 2007, 59(5):581-587.
134. Fakih M.G., Trump D.L., Muindi J.R., et al. A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors. Clin Cancer Res 2007, 13(4):1216-1223.
135. Muindi J.R., Johnson C.S., Trump D.L., et al. A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors. Cancer Chemother Pharmacol 2009, 65(1):33-40.
136. Muindi J.R., Modzelewski R.A., Peng Y., et al. Pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 in normal mice after systemic exposure to effective and safe antitumor doses. Oncology 2004, 66(1):62-66.
137. Dalhoff K., Dancey J., Astrup L., et al. A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma. Br J Cancer 2003, 89(2):252-257.
138. Evans T.R., Colston K.W., Lofts F.J., et al. A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer. Br J Cancer 2002, 86(5):680-685.
139. Gulliford T., English J., Colston K.W., et al. A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer. Br J Cancer 1998, 78(1):6-13.
140. Attia S., Eickhoff J., Wilding G., et al. Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer. Clin Cancer Res 2008, 14(8):2437-2443.
141. Liu G., Oettel K., Ripple G., et al. Phase I trial of 1alpha-hydroxyvitamin D(2) in patients with hormone refractory prostate cancer. Clin Cancer Res 2002, 8(9):2820-2827.
142. Liu G., Wilding G., Staab M.J., et al. Phase II study of 1alpha-hydroxyvitamin D(2) in the treatment of advanced androgen-independent prostate cancer. Clin Cancer Res 2003, 9(11):4077-4083.
143. Medioni J, Eickhoff J, Wilding G, et al. Dose finding and safety analysis of inecalcitol in combination with a docetaxel-prednisone regimen in hormone-refractory prostate cancer (HRPC) patients. J Clin Oncol 2009;27:15s[Suppl abstr: 151].
144. Schwartz G.G., Hall M.C., Stindt D., et al. Phase I/II study of 19-nor-1alpha-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancer. Clin Cancer Res 2005, 11(24 Pt 1):8680-8685.
145. Beer T.M., Eilers K.M., Garzotto M., et al. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 2003, 21(1):123-128.
146. Beer T.M., Ryan C.W., Venner P.M., et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT investigators. J Clin Oncol 2007, 25(6):669-674.
147. Beer T.M., Garzotto M., Katovic N.M. High-dose calcitriol and carboplatin in metastatic androgen-independent prostate cancer. Am J Clin Oncol 2004, 27(5):535-541.
148. Flaig T.W., Barqawi A., Miller G., et al. A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer. Cancer 2006, 107(2):266-274.